Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Dose Escalation And Expansion Study Of Pf-06801591 In Patients With Locally Advanced Or Metastatic Melanoma, Squamous Cell Head And Neck Cancer, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Urothelial Carcinoma Or Other Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1, Open-label, Dose Escalation And Expansion Study Of Pf-06801591 In Patients With Locally Advanced Or Metastatic Melanoma, Squamous Cell Head And Neck Cancer, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Urothelial Carcinoma Or Other Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sasanlimab (Primary) ; Sasanlimab (Primary)
  • Indications Adenocarcinoma; Endometrial cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 30 May 2024 Results published in the Onc.AI Media Release
    • 30 May 2024 According to Onc.AI media release, data from this study will be presented at the 2024 Annual Society of Clinical Oncology (ASCO)
    • 18 Mar 2022 Data from patients of this study were used to develop population PK model for sasanlimab, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top